NeurAxis (NASDAQ:NRXS – Get Free Report) and NovoCure (NASDAQ:NVCR – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, earnings, institutional ownership, dividends, valuation and risk.
Volatility and Risk
NeurAxis has a beta of 1.38, suggesting that its share price is 38% more volatile than the S&P 500. Comparatively, NovoCure has a beta of 0.99, suggesting that its share price is 1% less volatile than the S&P 500.
Valuation & Earnings
This table compares NeurAxis and NovoCure”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| NeurAxis | $5.32 million | 18.19 | -$14.63 million | ($0.78) | -9.87 |
| NovoCure | $655.35 million | 2.50 | -$136.23 million | ($1.30) | -10.82 |
NeurAxis has higher earnings, but lower revenue than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than NeurAxis, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
11.8% of NeurAxis shares are owned by institutional investors. Comparatively, 84.6% of NovoCure shares are owned by institutional investors. 21.1% of NeurAxis shares are owned by insiders. Comparatively, 6.6% of NovoCure shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Profitability
This table compares NeurAxis and NovoCure’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| NeurAxis | -492.76% | N/A | -641.25% |
| NovoCure | -21.25% | -44.00% | -15.85% |
Analyst Ratings
This is a summary of recent ratings and price targets for NeurAxis and NovoCure, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| NeurAxis | 0 | 1 | 1 | 0 | 2.50 |
| NovoCure | 1 | 4 | 2 | 0 | 2.14 |
NeurAxis presently has a consensus target price of $13.00, suggesting a potential upside of 68.83%. NovoCure has a consensus target price of $21.20, suggesting a potential upside of 50.68%. Given NeurAxis’ stronger consensus rating and higher possible upside, equities research analysts plainly believe NeurAxis is more favorable than NovoCure.
Summary
NeurAxis beats NovoCure on 9 of the 14 factors compared between the two stocks.
About NeurAxis
NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome. The company sells its products to healthcare companies, including hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is headquartered in Carmel, Indiana.
About NovoCure
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company’s TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.
Receive News & Ratings for NeurAxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeurAxis and related companies with MarketBeat.com's FREE daily email newsletter.
